TABRECTA — Total revenues
Incyte TABRECTA — Total revenues decreased by 15.5% to $6.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.3%, from $6.40M to $6.00M. Over 3 years (FY 2021 to FY 2025), TABRECTA — Total revenues shows an upward trend with a 37.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration or expanded clinical adoption, while a decrease may signal increased competition or loss of market share.
Detailed definition
This metric represents the total gross revenue generated from the sale and commercialization of a specific oncology ther...
Peer comparison
Comparable to product-specific net sales reported by other mid-to-large cap biopharmaceutical companies for their key oncology assets.
incy_segment_tabrecta_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.50M | $2.70M | $3.10M | $3.50M | $3.60M | $4.20M | $4.80M | $4.10M | $4.70M | $5.20M | $5.30M | $5.90M | $6.20M | $6.40M | $6.60M | $6.50M | $7.10M | $6.00M |
| QoQ Change | — | +8.0% | +14.8% | +12.9% | +2.9% | +16.7% | +14.3% | -14.6% | +14.6% | +10.6% | +1.9% | +11.3% | +5.1% | +3.2% | +3.1% | -1.5% | +9.2% | -15.5% |
| YoY Change | — | — | — | — | +44.0% | +20.0% | +33.3% | — | — | +23.8% | +10.4% | +43.9% | +31.9% | +23.1% | +24.5% | +10.2% | +14.5% | -6.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's tabrecta — total revenues?
- Incyte (INCY) reported tabrecta — total revenues of $6.00M in Q1 2026.
- How has Incyte's tabrecta — total revenues changed year-over-year?
- Incyte's tabrecta — total revenues decreased by 6.3% year-over-year, from $6.40M to $6.00M.
- What is the long-term trend for Incyte's tabrecta — total revenues?
- Over 3 years (2021 to 2025), Incyte's tabrecta — total revenues has grown at a 37.2% compound annual growth rate (CAGR), from $10.30M to $26.60M.
- What does tabrecta — total revenues mean?
- The total sales revenue generated by a specific pharmaceutical product.